The plaintiffs say that companies improperly marketed opioids, downplaying the addiction risks, and that big shipments were not flagged as suspicious.
Johnson & Johnson settled just before the trial began, and the nation's three largest drug distributions companies — AmerisourceBergen, Cardinal Health and McKesson — have all since settled.
Those four companies have since announced a tentative $26 billion nationwide settlement deal that would take months to finalize.
Last week, a federal bankruptcy judge gave conditional approval to a plan to allow OxyContin maker Purdue Pharma to settle some 3,000 claims it faces.
Opioids, including prescription painkillers and illicit drugs such as heroin and illegally produced fentanyl, have been linked to more than 500,000 deaths in the U.S. over the last two decades.
As settlements are reached, it means companies are starting to fund drug treatment and education programs.
Other trials are queued up across the U.S., including a federal trial next month over claims against pharmacies.